Radiation Sciences Department, Medical Research Institute, Alexandria University, Alexandria, Egypt.
lecturer of Cancer Management and Research Department, Medical Research Institute, Alexandria University, Alexandria, Egypt.
Asian Pac J Cancer Prev. 2024 May 1;25(5):1707-1713. doi: 10.31557/APJCP.2024.25.5.1707.
Radiation-induced lung disease is a potentially fatal, dose-limiting toxicity commonly seen after radiotherapy of thoracic malignancies, including breast cancer.
To evaluate and compare the early lung toxicity induced by 3D-CRT and IMRT radiotherapy treatment modalities in breast cancer female patients using biochemical, dosimetry and clinical data.
this study included 15 normal healthy controls, 15 breast cancer patients treated with IMRT, and 15 breast cancer patients treated with 3D-CRT. One blood sample was obtained from the control group and 3 blood samples were withdrawn from cases before RT, after RT and after 3 months of RT.
IMRT delivered higher radiation dose to the breast tumor and lower doses to the lung as an organ at risk. There was a non-significant increase in the serum levels of IL-6 before IMRT and 3D-CRT compared with its levels in the control group. There were significant increases in serum levels of IL-6 after RT (IMRT and 3DCRT) compared with its levels before RT. There was a non-significant decrease in the serum levels of IL-6 after 3 months of RT (IMRT and 3D-CRT) compared with its serum levels immediately after RT. There was a non-significant increase in the serum levels of SP-D before RT (IMRT and 3D-CRT) compared with its levels in the control group. There were significant-increases in serum levels of SP-D after RT (IMRT and 3D-CRT) compared with its levels before RT. There was a non-significant decrease in the serum levels of SP-D after 3 months of radiotherapy (IMRT and 3D-CRT) compared with its serum levels immediately after RT.
serum of levels IL-6 and SP-D can be used to diagnose the occurrence of early lung toxicity due to radiotherapy and the rate of recovery from radiation pneumonitis is apparent in case of IMRT than 3D-CRT.
放射性肺损伤是胸部恶性肿瘤放疗后常见的一种潜在致命性、剂量限制毒性，包括乳腺癌。
使用生化、剂量学和临床数据评估和比较 3D-CRT 和 IMRT 放疗治疗模式在乳腺癌女性患者中诱导的早期肺毒性。
本研究包括 15 名正常健康对照者、15 名接受 IMRT 治疗的乳腺癌患者和 15 名接受 3D-CRT 治疗的乳腺癌患者。从对照组中获得一份血样，从病例中提取 3 份血样，分别在 RT 前、RT 后和 RT 后 3 个月。
IMRT 对乳腺癌肿瘤给予更高的辐射剂量，对作为危险器官的肺给予较低的剂量。与对照组相比，在 IMRT 和 3D-CRT 之前，血清中 IL-6 的水平有非显著性升高。与 RT 前相比，RT（IMRT 和 3DCRT）后血清中 IL-6 的水平显著升高。与 RT 后立即相比，RT（IMRT 和 3D-CRT）后 3 个月血清中 IL-6 的水平略有下降。与对照组相比，在 RT 前（IMRT 和 3D-CRT）血清中 SP-D 的水平有非显著性升高。与 RT 前相比，RT（IMRT 和 3D-CRT）后血清中 SP-D 的水平显著升高。与 RT 后立即相比，RT（IMRT 和 3D-CRT）后 3 个月血清中 SP-D 的水平略有下降。
血清中 IL-6 和 SP-D 的水平可用于诊断放疗引起的早期肺毒性的发生，与 3D-CRT 相比，IMRT 从放射性肺炎中恢复的速度更快。
